Skip to main content
SpringerLink
Log in
Book cover

Molecular Pathology in Cancer Research pp 239–260Cite as

The Clinical Application of Proteomics

  • Chapter
  • First Online:

  • 1039 Accesses

Abstract

Proteins are key regulators of the biochemistry of cells and, therefore, in the maintenance of good health. It is important to both identify and quantify the proteins that are causative of a particular pathology since this information can inform the clinician as to both the selection of the correct treatment and monitor the success of its use. In the previous chapter, we described the methods used to analyse proteins. Here we turn our attention to the application of proteomics in the clinical context, outline the markers currently in use and describe in more depth several examples of proteins of clinical importance.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

CRC:

Colorectal cancer

CSF:

Cerebrospinal fluid

CVF:

Cervico vaginal fluid

DRE:

Digital rectal exam

ELISA:

Enzyme Linked Immunosorbent Assay

FDA:

Federal Drug Administration

HUPO:

Human Proteome Organisation

PSA:

Prostate-specific antigen

ROC:

Receiver operator characteristic curves

SOP:

Standard Operating Procedure

References

  1. Blonder J, Issaq HJ, Veenstra TD (2011) Proteomic biomarker discovery: it’s more than just mass spectrometry. Electrophoresis 32(13):1541–1548. doi:10.1002/elps.201000585

    CAS  PubMed  Google Scholar 

  2. Issaq HJ, Waybright TJ, Veenstra TD (2011) Cancer biomarker discovery: opportunities and pitfalls in analytical methods. Electrophoresis 32(9):967–975. doi:10.1002/elps.201000588

    Article  CAS  PubMed  Google Scholar 

  3. Wasinger VC, Cordwell SJ, Cerpa-Poljak A, Yan JX, Gooley AA, Wilkins MR, Duncan MW, Harris R, Williams KL, Humphery-Smith I (1995) Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 16(7):1090–1094

    Article  CAS  PubMed  Google Scholar 

  4. Blackstock WP, Weir MP (1999) Proteomics: quantitative and physical mapping of cellular proteins. Trends Biotechnol 17(3):121–127

    Article  CAS  PubMed  Google Scholar 

  5. Deribe YL, Pawson T, Dikic I (2010) Post-translational modifications in signal integration. Nat Struct Mol Biol 17(6):666–672. doi:10.1038/nsmb.1842

    Article  CAS  PubMed  Google Scholar 

  6. Bence-Jones H (1848) On a new substance occurring in the urine of a patient with mollities ossium. Philos Trans R Soc Lond 138:55–62

    Article  Google Scholar 

  7. Kyle RA (1994) Multiple myeloma: how did it begin? Mayo Clin Proc 69(7):680–683

    Article  CAS  PubMed  Google Scholar 

  8. Sinclair D, Dagg JH, Smith JG, Stott DI (1986) The incidence and possible relevance of Bence-Jones protein in the sera of patients with multiple myeloma. Br J Haematol 62(4):689–694

    Article  CAS  PubMed  Google Scholar 

  9. Polanski M, Anderson NL (2007) A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 1:1–48

    PubMed  PubMed Central  Google Scholar 

  10. Rifai N, Gillette MA, Carr SA (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24(8):971–983. doi:10.1038/nbt1235

    Article  CAS  PubMed  Google Scholar 

  11. Whiteley G (2008) Bringing diagnostic technologies to the clinical laboratory: rigor, regulation, and reality. Proteomics Clin Appl 2(10-11):1378–1385. doi:10.1002/prca.200780170

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Liu X, Valentine SJ, Plasencia MD, Trimpin S, Naylor S, Clemmer DE (2007) Mapping the human plasma proteome by SCX-LC-IMS-MS. J Am Soc Mass Spectrom 18(7):1249–1264. doi:10.1016/j.jasms.2007.04.012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1(11):845–867

    Article  CAS  PubMed  Google Scholar 

  14. States DJ, Omenn GS, Blackwell TW, Fermin D, Eng J, Speicher DW, Hanash SM (2006) Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol 24(3):333–338. doi:10.1038/nbt1183

    Article  CAS  PubMed  Google Scholar 

  15. Schiess R, Wollscheid B, Aebersold R (2009) Targeted proteomic strategy for clinical biomarker discovery. Mol Oncol 3(1):33–44. doi:10.1016/j.molonc.2008.12.001

    Article  CAS  PubMed  Google Scholar 

  16. Anderson NL, Polanski M, Pieper R, Gatlin T, Tirumalai RS, Conrads TP, Veenstra TD, Adkins JN, Pounds JG, Fagan R, Lobley A (2004) The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 3(4):311–326. doi:10.1074/mcp.M300127-MCP200

    Article  CAS  PubMed  Google Scholar 

  17. Randall SA, McKay MJ, Molloy MP (2010) Evaluation of blood collection tubes using selected reaction monitoring MS: implications for proteomic biomarker studies. Proteomics 10(10):2050–2056. doi:10.1002/pmic.200900517

    Article  CAS  PubMed  Google Scholar 

  18. Bergen HR 3rd, Zeldenrust SR, Butz ML, Snow DS, Dyck PJ, Klein CJ, O’Brien JF, Thibodeau SN, Muddiman DC (2004) Identification of transthyretin variants by sequential proteomic and genomic analysis. Clin Chem 50(9):1544–1552. doi:10.1373/clinchem.2004.033266

    Article  CAS  PubMed  Google Scholar 

  19. Bergen HR, Lacey JM, O’Brien JF, Naylor S (2001) Online single-step analysis of blood proteins: the transferrin story. Anal Biochem 296(1):122–129. doi:10.1006/abio.2001.5232

    Article  CAS  PubMed  Google Scholar 

  20. Nepomuceno AI, Mason CJ, Muddiman DC, Bergen HR 3rd, Zeldenrust SR (2004) Detection of genetic variants of transthyretin by liquid chromatography-dual electrospray ionization fourier-transform ion-cyclotron-resonance mass spectrometry. Clin Chem 50(9):1535–1543. doi:10.1373/clinchem.2004.033274

    Article  CAS  PubMed  Google Scholar 

  21. Paik JH, Choe G, Kim H, Choe JY, Lee HJ, Lee CT, Lee JS, Jheon S, Chung JH (2011) Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 6(3):466–472. doi:10.1097/JTO.0b013e31820b82e8

    Article  PubMed  Google Scholar 

  22. Bertino G, Neri S, Bruno CM, Ardiri AM, Calvagno GS, Malaguarnera M, Toro A, Clementi S, Bertino N, Di Carlo I (2011) Diagnostic and prognostic value of alpha-fetoprotein, des-gamma-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med 102(5):363–371

    CAS  PubMed  Google Scholar 

  23. Sherman M (2011) Current status of alpha-fetoprotein testing. Gastroenterol Hepatol (N Y) 7(2):113–114

    Google Scholar 

  24. Fonseca R, San Miguel J (2007) Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am 21(6):1115–1140. doi:10.1016/j.hoc.2007.08.010, ix

    Article  PubMed  Google Scholar 

  25. Cole LA (2012) hCG, the wonder of today’s science. Reprod Biol Endocrinol 10:24. doi:10.1186/1477-7827-10-24

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Stenman UH (2004) Standardization of assays for human chorionic gonadotropin. Clin Chem 50(5):798–800. doi:10.1373/clinchem.2003.031013

    Article  CAS  PubMed  Google Scholar 

  27. Stenman UH, Alfthan H, Hotakainen K (2004) Human chorionic gonadotropin in cancer. Clin Biochem 37(7):549–561. doi:10.1016/j.clinbiochem.2004.05.008

    Article  CAS  PubMed  Google Scholar 

  28. Dekking E, van der Velden VH, Bottcher S, Bruggemann M, Sonneveld E, Koning-Goedheer A, Boeckx N, Lucio P, Sedek L, Szczepanski T, Kalina T, Kovac M, Evans P, Hoogeveen PG, Flores-Montero J, Orfao A, Comans-Bitter WM, Staal FJ, van Dongen JJ (2010) Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay. Best Pract Res Clin Haematol 23(3):333–345. doi:10.1016/j.beha.2010.09.010

    Article  CAS  PubMed  Google Scholar 

  29. Foroni L, Wilson G, Gerrard G, Mason J, Grimwade D, White HE, de Castro DG, Austin S, Awan A, Burt E, Clench T, Farruggia J, Hancock J, Irvine AE, Kizilors A, Langabeer S, Milner BJ, Nickless G, Schuh A, Sproul A, Wang L, Wickham C, Cross NC (2011) Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia. Br J Haematol 153(2):179–190. doi:10.1111/j.1365-2141.2011.08603.x

    Article  CAS  PubMed  Google Scholar 

  30. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One 7(10), e47054. doi:10.1371/journal.pone.0047054

    Article  PubMed  PubMed Central  Google Scholar 

  31. Cabrera-Abreu JC, Smellie WS, Bowley R, Shaw N (2012) Best practice in primary care pathology: review 13. J Clin Pathol 65(2):97–100. doi:10.1136/jclinpath-2011-200292

    Article  CAS  PubMed  Google Scholar 

  32. Moore LE, Pfeiffer RM, Zhang Z, Lu KH, Fung ET, Bast RC Jr (2012) Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 118(1):91–100. doi:10.1002/cncr.26241

    Article  CAS  PubMed  Google Scholar 

  33. Ahmed SR, Ball DW (2011) Clinical review: incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment. J Clin Endocrinol Metab 96(5):1237–1245. doi:10.1210/jc.2010-2359

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Bacolod MD, Barany F (2011) Molecular profiling of colon tumors: the search for clinically relevant biomarkers of progression, prognosis, therapeutics, and predisposition. Ann Surg Oncol 18(13):3694–3700. doi:10.1245/s10434-011-1615-5

    Article  PubMed  PubMed Central  Google Scholar 

  35. Grunnet M, Sorensen JB (2012) Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 76(2):138–143. doi:10.1016/j.lungcan.2011.11.012

    Article  CAS  PubMed  Google Scholar 

  36. Freedman A (2012) Follicular lymphoma: 2012 update on diagnosis and management. Am J Hematol 87(10):988–995. doi:10.1002/ajh.23313

    Article  PubMed  Google Scholar 

  37. Jacobson CA, Freedman AS (2012) Early stage follicular lymphoma, current management and controversies. Curr Opin Oncol 24(5):475–479. doi:10.1097/CCO.0b013e328356898b

    Article  PubMed  Google Scholar 

  38. Ramachandran R, Bech P, Murphy KG, Dhillo WS, Meeran KM, Chapman RS, Caplin M, Ghatei MA, Bloom SR, Martin NM (2012) Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays. Clin Endocrinol (Oxf) 76(6):831–836. doi:10.1111/j.1365-2265.2011.04319.x

    Article  CAS  Google Scholar 

  39. Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S, Waldum HL (2004) Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol 39(10):969–973. doi:10.1080/00365520410003362

    Article  CAS  PubMed  Google Scholar 

  40. Caraway NP, Khanna A, Fernandez RL, Payne L, Bassett RL Jr, Zhang HZ, Kamat A, Katz RL (2010) Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study. Cancer Cytopathol 118(5):259–268. doi:10.1002/cncy.20099

    Article  PubMed  PubMed Central  Google Scholar 

  41. De Petris L, Branden E, Herrmann R, Sanchez BC, Koyi H, Linderholm B, Lewensohn R, Linder S, Lehtio J (2011) Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer. Eur J Cancer 47(1):131–137. doi:10.1016/j.ejca.2010.08.006

    Article  PubMed  Google Scholar 

  42. Holdenrieder S, Stieber P, Liska V, Treska V, Topolcan O, Dreslerova J, Matejka VM, Finek J, Holubec L (2012) Cytokeratin serum biomarkers in patients with colorectal cancer. Anticancer Res 32(5):1971–1976

    CAS  PubMed  Google Scholar 

  43. Cheng L, Alexander RE, Maclennan GT, Cummings OW, Montironi R, Lopez-Beltran A, Cramer HM, Davidson DD, Zhang S (2012) Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 25(3):347–369. doi:10.1038/modpathol.2011.215

    Article  CAS  PubMed  Google Scholar 

  44. Lim E, Metzger-Filho O, Winer EP (2012) The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park) 26(8):688–694, 696

    Google Scholar 

  45. Jeong S, Park Y, Cho Y, Kim YR, Kim HS (2012) Diagnostic values of urine CYFRA21-1, NMP22, UBC, and FDP for the detection of bladder cancer. Clin Chim Acta 414C:93–100. doi:10.1016/j.cca.2012.08.018

    Google Scholar 

  46. Montagnana M, Danese E, Giudici S, Franchi M, Guidi GC, Plebani M, Lippi G (2011) HE4 in ovarian cancer: from discovery to clinical application. Adv Clin Chem 55:1–20

    Article  CAS  PubMed  Google Scholar 

  47. Molina R, Escudero JM, Munoz M, Auge JM, Filella X (2012) Circulating levels of HER-2/neu oncoprotein in breast cancer. Clin Chem Lab Med 50(1):5–21. doi:10.1515/cclm.2011.822

    Article  CAS  PubMed  Google Scholar 

  48. Maleddu A, Pantaleo MA, Nannini M, Biasco G (2011) The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting. J Transl Med 9:75. doi:10.1186/1479-5876-9-75

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Heideman DA, Lurkin I, Doeleman M, Smit EF, Verheul HM, Meijer GA, Snijders PJ, Thunnissen E, Zwarthoff EC (2012) KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA. J Mol Diagn 14(3):247–255. doi:10.1016/j.jmoldx.2012.01.011

    Article  CAS  PubMed  Google Scholar 

  50. Venkitaraman R, Johnson B, Huddart RA, Parker CC, Horwich A, Dearnaley DP (2007) The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours. BJU Int 100(1):30–32. doi:10.1111/j.1464-410X.2007.06905.x

    Article  CAS  PubMed  Google Scholar 

  51. Shariat SF, Savage C, Chromecki TF, Sun M, Scherr DS, Lee RK, Lughezzani G, Remzi M, Marberger MJ, Karakiewicz PI, Vickers AJ (2011) Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. Cancer 117(13):2892–2897. doi:10.1002/cncr.25903

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Lumen N, Fonteyne V, De Meerleer G, De Visschere P, Ost P, Oosterlinck W, Villeirs G (2012) Screening and early diagnosis of prostate cancer: an update. Acta Clin Belg 67(4):270–275

    CAS  PubMed  Google Scholar 

  53. Cox AE, LeBeau SO (2011) Diagnosis and treatment of differentiated thyroid carcinoma. Radiol Clin North Am 49(3):453–462. doi:10.1016/j.rcl.2011.02.006, vi

    Article  PubMed  Google Scholar 

  54. Spencer CA (2011) Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab 96(12):3615–3627. doi:10.1210/jc.2011-1740

    Article  CAS  PubMed  Google Scholar 

  55. Iwaki T, Urano T, Umemura K (2012) PAI-1, progress in understanding the clinical problem and its aetiology. Br J Haematol 157(3):291–298. doi:10.1111/j.1365-2141.2012.09074.x

    Article  CAS  PubMed  Google Scholar 

  56. Fung ET (2010) A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 56(2):327–329. doi:10.1373/clinchem.2009.140855

    Article  CAS  PubMed  Google Scholar 

  57. Retel VP, Joore MA, van Harten WH (2012) Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance. Breast Cancer Res Treat 131(2):627–636. doi:10.1007/s10549-011-1769-7

    Article  PubMed  Google Scholar 

  58. Lovgren J, Piironen T, Overmo C, Dowell B, Karp M, Pettersson K, Lilja H, Lundwall A (1995) Production of recombinant PSA and HK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun 213(3):888–895

    Article  CAS  PubMed  Google Scholar 

  59. Pettersson K, Piironen T, Seppala M, Liukkonen L, Christensson A, Matikainen MT, Suonpaa M, Lovgren T, Lilja H (1995) Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex. Clin Chem 41(10):1480–1488

    CAS  PubMed  Google Scholar 

  60. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Paez A, Maattanen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366(11):981–990. doi:10.1056/NEJMoa1113135

    Article  PubMed  Google Scholar 

  61. Tigue CC, Fitzner KA, Alkhatib M, Schmid E, Bennett CL (2007) The value of innovation: the economics of targeted drugs for cancer. Target Oncol 2(2):113–119. doi:10.1007/S11523-007-0043-8

    Article  Google Scholar 

  62. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A (2009) Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205(12):858–862. doi:10.1016/J.Prp.2009.07.010

    Article  CAS  PubMed  Google Scholar 

  63. Shushan B (2010) A review of clinical diagnostic applications of liquid chromatography-tandem mass spectrometry. Mass Spectrom Rev 29(6):930–944. doi:10.1002/mas.20295

    Article  CAS  PubMed  Google Scholar 

  64. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, Spiegelman CH, Zimmerman LJ, Ham AJL, Keshishian H, Hall SC, Allen S, Blackman RK, Borchers CH, Buck C, Cardasis HL, Cusack MP, Dodder NG, Gibson BW, Held JM, Hiltke T, Jackson A, Johansen EB, Kinsinger CR, Li J, Mesri M, Neubert TA, Niles RK, Pulsipher TC, Ransohoff D, Rodriguez H, Rudnick PA, Smith D, Tabb DL, Tegeler TJ, Variyath AM, Vega-Montoto LJ, Wahlander A, Waldemarson S, Wang M, Whiteaker JR, Zhao L, Anderson NL, Fisher SJ, Liebler DC, Paulovich AG, Regnier FE, Tempst P, Carr SA (2009) Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma (vol 27, pg 633, 2009). Nat Biotechnol 27(9):864. doi:10.1038/Nbt0909-864b

    Article  CAS  Google Scholar 

  65. Ruppen-Canas I, Lopez-Casas PP, Garcia F, Ximenez-Embun P, Munoz M, Morelli MP, Real FX, Serna A, Hidalgo M, Ashman K (2012) An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity. Proteomics 12(9):1319–1327. doi:10.1002/pmic.201100611

    Article  CAS  PubMed  Google Scholar 

  66. Wang Q, Chaerkady R, Wu J, Hwang HJ, Papadopoulos N, Kopelovich L, Maitra A, Matthaei H, Eshleman JR, Hruban RH, Kinzler KW, Pandey A, Vogelstein B (2011) Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci U S A 108(6):2444–2449. doi:10.1073/pnas.1019203108

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Rauh M (2012) LC-MS/MS for protein and peptide quantification in clinical chemistry. J Chromatogr B Analyt Technol Biomed Life Sci 883–884:59–67. doi:10.1016/j.jchromb.2011.09.030

    Article  PubMed  Google Scholar 

  68. Farrah T, Deutsch EW, Kreisberg R, Sun Z, Campbell DS, Mendoza L, Kusebauch U, Brusniak MY, Huttenhain R, Schiess R, Selevsek N, Aebersold R, Moritz RL (2012) PASSEL: The PeptideAtlas SRM Experiment Library. Proteomics. doi:10.1002/pmic.201100515

    Google Scholar 

  69. Ciccimaro E, Blair IA (2010) Stable-isotope dilution LC-MS for quantitative biomarker analysis. Bioanalysis 2(2):311–341. doi:10.4155/bio.09.185

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW (2004) Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res 3(2):235–244

    Article  CAS  PubMed  Google Scholar 

  71. Whiteaker JR, Zhao L, Anderson L, Paulovich AG (2009) An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol Cell Proteomics. doi:10.1074/mcp.M900254-MCP200. pii: M900254-MCP200

    Google Scholar 

  72. Anderson NL, Jackson A, Smith D, Hardie D, Borchers C, Pearson TW (2009) SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol Cell Proteomics 8(5):995–1005. doi:10.1074/Mcp.M800446-Mcp200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Kathiresan S, Gona P, Larson MG, Vita JA, Mitchell GF, Tofler GH, Levy D, Newton-Cheh C, Wang TJ, Benjamin EJ, Vasan RS (2006) Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation 113(7):938–945. doi:10.1161/CIRCULATIONAHA.105.580233

    Article  CAS  PubMed  Google Scholar 

  74. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D’Agostino RB, Vasan RS (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355(25):2631–2639. doi:10.1056/NEJMoa055373

    Article  CAS  PubMed  Google Scholar 

  75. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P, Ward DC (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 102(21):7677–7682. doi:10.1073/pnas.0502178102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Mitchell MD, Rice G (2102) Early pregnancy screening for complications of pregnancy: proteomic profiling approaches. In: Zheng J (ed) Recent advances in research on the human placenta. Intech

    Google Scholar 

  77. Brian M. Nolen and Anna E. Lokshin (2013) Biomarker Testing for Ovarian Cancer: Clinical Utility of Multiplex Assays. Mol Diagn Ther. Jun; 17(3): 139–146

    Google Scholar 

Download references

Acknowledgments

Keith Ashman acknowledges and thanks the Rotary Club of Williamstown, Victoria, Australia for partial salary support through the RoCan program. Gregory Rice was in receipt of an NHMRC Principal Research Fellowship.

Author information

Authors and Affiliations

  1. University of Queensland Centre for Clinical Research, Building 71/918, Royal Brisbane & Women’s Hospital Campus, Herston, QLD, 4029, Australia

    Keith Ashman, Murray Mitchell & Gregory Rice

Authors
  1. Keith Ashman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Murray Mitchell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gregory Rice
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Keith Ashman or Gregory Rice .

Editor information

Editors and Affiliations

  1. UQ Centre for Clinical Research, The Royal Brisbane and Women’s Hospital, University of Queensland and Pathology Queensland, Brisbane, Queensland, Australia

    Sunil R. Lakhani

  2. Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia

    Stephen B. Fox

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media LLC

About this chapter

Cite this chapter

Ashman, K., Mitchell, M., Rice, G. (2016). The Clinical Application of Proteomics. In: Lakhani, S., Fox, S. (eds) Molecular Pathology in Cancer Research. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-6643-1_11

Download citation

Publish with us

Policies and ethics

Search

Navigation